

COPY OF PAPERS
ORIGINALLY FILED

1617



Attorney Docket No.: 6225.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

In re Application of: Koch et al

Serial No.: 10/016,858

Group Art Unit: 1617

Filed: December 14, 2001

Examiner: San Ming R. Hui

Confirmation No.: 7430

For: Hormone Composition

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on August 29, 2002.

Carol McFarlane-Fishberg
(name of person mailing paper)

Carol McFarlane-Fishberg
(signature of person mailing paper)



23650

PATENT TRADEMARK OFFICE

COPY OF PAPERS
ORIGINALLY FILED

9/selection
w/ traverse
PATENT *c/m*
8-29-02



Attorney Docket No.: 6225.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Koch et al

Application No.: 10/016,858

Group Art Unit: 1617

RECEIVED

Filed: December 14, 2001

Examiner: San Ming Hui

SEP 09 2002

Confirmation No.: 7430

TECH CENTER 1600/2900

For: Hormone Composition

RESPONSE TO RESTRICTION REQUIREMENT

Ref
9-13-02

Commissioner for Patents
Washington, DC 20231

Sir:

This paper is being filed in response to the Office Action mailed July 30, 2002, in which the Examiner required restriction of the claims to one of the following invention groups: Group I (claims 29-32 and 34), directed to a tablet comprising 17-b-estradiol, and Group II (claims 35-53), directed to a method of treating atopic vaginitis.

In response to this requirement, Applicants hereby elect with traverse the invention of Group II (claims 35-53).

Applicants reserve the right to file continuing applications directed to the nonelected subject matter.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: August 29, 2002

Reza Green

Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE